Abeona Therapeutics - Public Comps and Valuation Multiples

Abeona Therapeutics Overview

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Founded

1974

HQ

Employees

136

Website

abeonatherapeutics.com

Sectors

Drug Development & Therapeutics
Genomics & Personalized Medicine
BioTech
DeepTech

Financials

LTM Revenue $19.2M

Last FY EBITDA -$56.6M

EV

$92.1M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Abeona Therapeutics Financials

As of August 2025, Abeona Therapeutics reported last 12-month revenue of $19.2M.

In the same period, Abeona Therapeutics generated $15.9M in LTM gross profit and $33.3M in net income.

See Abeona Therapeutics valuation multiples based on analyst estimates

Abeona Therapeutics P&L

In the most recent fiscal year, Abeona Therapeutics reported EBITDA of -$56.6M.

Abeona Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Abeona Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$19.2M	XXX	n/a	XXX	XXX	XXX
Gross Profit	$15.9M	XXX	n/a	XXX	XXX	XXX
Gross Margin	83%	XXX	n/a	XXX	XXX	XXX
EBITDA	n/a	XXX	-$56.6M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$68.2M	XXX	-$64.2M	XXX	XXX	XXX
EBIT Margin	-355%	XXX	n/a	XXX	XXX	XXX
Net Profit	$33.3M	XXX	-$63.7M	XXX	XXX	XXX
Net Margin	173%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Abeona Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $19.2M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$19.2M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$15.9M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	82.7% gross margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$56.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$68.2M	Analyst estimates available to subscribers	-$64.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-354.6% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$33.3M	Analyst estimates available to subscribers	-$63.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	173.2% net profit margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Abeona Therapeutics

This financial data table provides comprehensive performance metrics for Abeona Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Abeona Therapeutics generated $19.2M in revenue over the last twelve months.
Gross profit for the last twelve months was $15.9M.
Net income over the last twelve months reached $33.3M.

Fiscal Year Performance

Fiscal year EBITDA was -$56.6M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Abeona Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Abeona Therapeutics Stock Performance

Abeona Therapeutics has current market cap of $294M, and EV of $92.1M.

Market Cap Evolution

Abeona Therapeutics Stock Data

As of September 17, 2025, Abeona Therapeutics's stock price is $6.

See Abeona Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$92.1M	$294M	XXX	XXX	XXX	XXX	$0.37

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Abeona Therapeutics Valuation Multiples

Abeona Therapeutics's trades at 26.3x EV/Revenue multiple, and -1.6x EV/EBITDA.

See valuation multiples for Abeona Therapeutics and 15K+ public comps

Abeona Therapeutics Financial Valuation Multiples

As of September 17, 2025, Abeona Therapeutics has market cap of $294M and EV of $92.1M.

Equity research analysts estimate Abeona Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Abeona Therapeutics has a P/E ratio of 8.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$294M	XXX	$294M	XXX	XXX	XXX
EV (current)	$92.1M	XXX	$92.1M	XXX	XXX	XXX
EV/Revenue	4.8x	XXX	26.3x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-1.6x	XXX	XXX	XXX
EV/EBIT	-1.4x	XXX	-1.4x	XXX	XXX	XXX
EV/Gross Profit	5.8x	XXX	n/a	XXX	XXX	XXX
P/E	8.8x	XXX	-4.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-1.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Abeona Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Abeona Therapeutics Margins & Growth Rates

Abeona Therapeutics's last 12 month revenue growth is 372%

Abeona Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.

Abeona Therapeutics's rule of 40 is -1073% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Abeona Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Abeona Therapeutics and other 15K+ public comps

Abeona Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	372%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	-1073%	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial